HER2-Positive Breast Cancer

By Sara Hurvitz, MD and Kelly McCann
NT$3,350 NT$3,015

Get a quick, expert overview of clinically-focused topics and guidelines that are relevant to testing for HER2, which contributes to approximately 25% of breast cancers today. This concise resource by Drs. Sara Hurvitz, and Kelly McCann consolidates today's available information on this growing topic into one convenient resource, making it an ideal, easy-to-digest reference for practicing and trainee oncologists.

  • Covers the diagnosis, treatments and targeted therapies, and management of breast cancers that are HER2-positive.
  • Contains sections on background and testing, advanced disease, therapeutics, and toxicity considerations.
  • Includes a timely section on innovative future therapies.
ISBN 9780323581226
作者資訊 By Sara Hurvitz, MD and Kelly McCann
Pp Authortext Hurvitz & McCann
Table of Content


1. The HER2 alteration in breast cancer

2. HER2 testing in the era of changing guidelines

Advanced Disease

3. Optimal first-line treatment of HER2+ advanced disease

4. Second line therapy and beyond

5. HER2+ CNS metastases


6. Neoadjuvant therapy

7. Adjuvant therapy

8. Outcomes based on HR status in early stage disease

9. De-escalation of therapy for small tumor

Toxicity considerations

10. Cardiac toxicity of HER2-targeted regimens

11. Non-cardiac toxicity of HER2-targeted therapy

Therapies on the horizon

12. Targeting other pathways active in HER2+ disease (CDK4/6, VEGF, PI3K, mTOR, FGFR, PARP, antibody-drug conjugates, etc)

13. Harnessing the immune system in HER2+ disease

14. Biosimilars

E-ISBN 9780323581233
Imprint Elsevier
出版日期 16-08-2018
Pages 250
Trim 235 x 191 (7 1/2 x 9 1/4)
只有已註冊的使用者可撰寫評論.請 登入註冊.

Back to top